Advertisement

Current Urology Reports

, Volume 14, Issue 6, pp 585–594 | Cite as

The use of PDE-5 Inhibitors in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

  • Casey Lythgoe
  • Kevin T. McVaryEmail author
Benign Prostatic Hyperplasia (K McVary and S Kaplan, Section Editors)

Abstract

The relationship between lower urinary tract symptoms secondary to BPH and ED has recently been the subject of significant research due to the prevalence of both conditions concomitantly existing in older men. Many large-scale studies have demonstrated an association between erectile dysfunction and lower urinary tract symptoms. Although the mechanisms underlying the relationship between LUTS and ED are not fully elucidated, several theories are currently proposed in literature: the nitric oxide/cGMP pathway, RhoA/Rho-kinase signaling, pelvic atherosclerosis associated with chronic hypoxia, and autonomic adrenergic hyperactivity. The mechanisms by which these pathways affect the bladder, prostate, pelvic vasculature and spinal cord are also the subject of current research. In this chapter, we examine the randomized, placebo-controlled trials that have evaluated the use of PDE-5Is in LUTS, as well as randomized, controlled trials (RCTs) researching combination PDE-5Is and alpha blockers.

Keywords

PDE-5 INHIBITORS Benign Prostatic Hyperplasia AUA Symptom Index (AUA-SI) Lower Urinary Tract Symptoms (LUTS) 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Dr. Casey Lythgoe reported no potential conflicts of interest relevant to this article.

Dr. Kevin McVary received consultancies and honoraria from Allergan, Lilly/ICOS, NxThera, and Watson Pharmaceuticals. Dr. McVary received honoraria and payment for the development of educational presentations including service on speakers’ bureaus from GSK.

Dr. McVary serves as a Section Editor for Current Urology Reports.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of outstanding importance

  1. 1.
    Nicolosi A, Moreira Jr ED, Shirai M, et al. Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction. Urology. 2003;61:201–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Lukacs B, Leplège A, Thibault P, et al. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results. Urology. 1996;48(5):731–40.PubMedCrossRefGoogle Scholar
  3. 3.
    Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44(6):637–49.PubMedCrossRefGoogle Scholar
  4. 4.
    Hansen BJ, Flyger H, Brasso K, Schou J, Nordling J, Thorup Andersen J, et al. Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia. Br J Urol. 1995;76(4):451–8.PubMedCrossRefGoogle Scholar
  5. 5.
    •• Wein AJ, Coyne KS, Tubaro A, et al. The impact of lower urinary tract symptoms on male sexual health: EpiLUTS. BJU Int. 2009;103 Suppl 3:33–41. doi: 10.1111/j.1464-410X.2009.08447.x.19. The EpiLUTS study was one of the first large-scale studies to demonstrate the relationship between LUTS and ED..PubMedCrossRefGoogle Scholar
  6. 6.
    Gacci M, Eardley I, Giuliano F, et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2011;60(4):809–25. doi: 10.1016/j.eururo.2011.06.037. Epub 2011 Jun 29.PubMedCrossRefGoogle Scholar
  7. 7.
    Kedia GT, Uckert S, Jonas U, Kuczyk MA, Burchardt M. The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. World J Urol. 2008;26:603–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Podlasek CA, Bond CW, McVary KT, et al. Analysis of Changes in Nitric Oxide Synthase Signaling in BB/WOR Diabetic Prostate. Androl. Feb 15, 2012.Google Scholar
  9. 9.
    Richter K, Heuer O, Uckert S, Stief CG, Jonas U, Wolf G. Immunocytochemical distribution of nitric oxide synthases in the human prostate [Abstract 347]. J Urol. 2004;171(Suppl):262–6.Google Scholar
  10. 10.
    Bloch W, Klotz T, Loch C, Schmidt G, Engelmann U, Addicks K. Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate. 1997;33:1–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Zhao C, Kim SH, Lee SW, Jeon JH, Kang KK, Choi SB, et al. Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int. 2011;107(12):1943–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Guh JH, Hwang TL, Ko FN, et al. Antiproliferative effect in human prostatic smooth muscle cells by nitric oxide donor. Mol Pharmacol. 1998;53:467–74.PubMedGoogle Scholar
  13. 13.
    Montorsi F, Corbin J, Phillips S. Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention. J Sex Med. 2004;1(3):322–36.PubMedCrossRefGoogle Scholar
  14. 14.
    Sandra Filippi, Annamaria Morelli, Peter Sandner, Benedetta Fibbi, Rosa Mancina, Mirca Marini, Mauro Gacci, Linda Vignozzi, Gabriella Barbara Vannelli, Marco Carini, Gianni Forti, and Mario Maggi Characterization and Functional Role of Androgen-Dependent PDE5 Activity in the Bladder Endocrinology. 2007;148(3):1019–29.Google Scholar
  15. 15.
    Morelli A, Filippi S, Sandner P, Fibbi B, Chavalmane AK, Silvestrini E, et al. Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats. J Sex Med. 2009;6(6):1594–608.PubMedCrossRefGoogle Scholar
  16. 16.
    Chang S, Hypolite JA, Changolkar A, Wein AJ, Chacko S, DiSanto ME. Increased contractility of diabetic rabbit corpora smooth muscle in response to endothelin is mediated via Rho-kinase beta. Int J Impot Res. 2003;15:53–62.PubMedCrossRefGoogle Scholar
  17. 17.
    Bivalacqua TJ, Champion HC, Usta MF, Cellek S, Chitaley K, Webb RC, et al. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in thepenis: A mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci U S A. 2004;101:9121–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Vignozzi L, Morelli A, Filippi S, Ambrosini S, Mancina R, Luconi M, et al. Testosterone regulates RhoA/Rho-kinase signaling in two distinct animal models of chemical diabetes. J Sex Med. 2007;4:620–32.PubMedCrossRefGoogle Scholar
  19. 19.
    Mouli S. McVary KT PDE5 inhibitors for LUTS. Prostate Cancer Prostatic Dis. 2009;12(4):316–24. doi: 10.1038/pcan.2009.27. Epub 2009 Aug 18.PubMedCrossRefGoogle Scholar
  20. 20.
    Tarcan T, Azadzoi KM, Siroky MB, Goldstein I, Krane RJ. Age related erectile and voiding dysfunction: the role of arterial insufficiency. Brit J Urol. 1998;82 Suppl 1:26–33.PubMedGoogle Scholar
  21. 21.
    Azadzoi KM, Tarcan T, Siroky MB, Krane RJ. Atherosclerosis induced chronic ischemia causes bladder fibrosis and noncompliance in the rabbit. J Urol. 1999;161:1626–35.PubMedCrossRefGoogle Scholar
  22. 22.
    Azadozoi K, Tarcan T, Kozlowski R, Krane R, Siroky M. Overactivity and Structural Changes in the Chronically Ischemic Bladder. J Urol. 1999;162(5):1768–78.CrossRefGoogle Scholar
  23. 23.
    Zhang H-Y, Phan SH. Inhibition of Myofibroblast Apoptosis by Transforming Growth Factor β1. Am J Respir Cell Mol Biol. 1999;21:658–65.PubMedCrossRefGoogle Scholar
  24. 24.
    Kozlowski R, Kershen RT, Siroky MB, Krane RJ, Azadzoi KM. Chronic ischemia alters prostate structure and reactivity in rabbits. J Urol. 2001;165:1019–26.PubMedCrossRefGoogle Scholar
  25. 25.
    Azadozoi KM et al. Chronic ischemia increases prostatic smooth muscle contraction in the rabbit. J Urol. 2003;170:659–63.CrossRefGoogle Scholar
  26. 26.
    Papapetropoulos A, García-Cardeña G, Madri JA, Sessa WC. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest. 1997;100(12):3131–9.PubMedCrossRefGoogle Scholar
  27. 27.
    McVary KT. Sexual Function and Alpha-Blockers. Rev Urol. 2005;7 Suppl 8:S3–11.PubMedGoogle Scholar
  28. 28.
    Hammarsten J, Hogstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press. 1999;8:29.PubMedCrossRefGoogle Scholar
  29. 29.
    Meigs JB, Mohr B, Barry MJ, et al. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol. 2001;54:935.PubMedCrossRefGoogle Scholar
  30. 30.
    McVary KT, Rademaker A, Lloyd GL, et al. Autonomic Nervous System Overactivity in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. J Urol. 2005;174:1327–433.PubMedCrossRefGoogle Scholar
  31. 31.
    Hale TM, Okabe H, Bushfield TL, et al. Recovery of erectile function after brief aggressive antihypertensive therapy. J Urol. 2002;168:348–54.PubMedCrossRefGoogle Scholar
  32. 32.
    Morelli A, Sarchielli E, Comeglio P, Filippi S, Mancina R, Gacci M, et al. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med. 2011;8(10):2746–60.PubMedCrossRefGoogle Scholar
  33. 33.
    Füllhase C, Hennenberg M, Giese A, Schmidt M, Strittmatter F, Soler R, Gratzke C, Andersson KE, Stief C. Presence of phosphodiesterase type 5 (PDE5) in the spinal cord and its involvement in bladder outflow obstruction related bladder overactivity. J Urol. 2013 Mar 29. doi:  10.1016/j.juro.2013.03.112.
  34. 34.
    • Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC. Sildenafil influences lower urinary tract symptoms. BJU Int. 2002;90(9):836–9. The original report detailing the influence of Sildenafil on LUTS..PubMedCrossRefGoogle Scholar
  35. 35.
    Mulhall JP, Guhring P, Parker M, Hopps C. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med. 2006;3(4):662–7.PubMedCrossRefGoogle Scholar
  36. 36.
    • Kevin T. McVary,William Monnig, Joseph L. Camps, Jr., Jay M. Young, Li-Jung Tseng and Gene van den Ende Sildenafil Citrate Improves Erectile Function and Urinary Symptoms in Men With Erectile Dysfunction and Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Randomized, Double-Blind Trial. Journal of Urology March. 2007;177:1071–1077. Randomized placebo-controlled study investigating the effect of Sildenafil on LUTS. Google Scholar
  37. 37.
    •• McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, et al. Tadalafil Relieves Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. J Urol. 2007;177:1401–7. Randomized placebo-controlled study investigating the effect of Tadalafil on LUTS using dose escalation..PubMedCrossRefGoogle Scholar
  38. 38.
    • Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A Randomised, Placebo-Controlled Study to Assess the Efficacy of Twice Daily Vardenafil in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Eur Urol. 2008;53:1236–44. Randomized placebo-controlled study investigating the effect of Vardenafil on LUTS.PubMedCrossRefGoogle Scholar
  39. 39.
    • Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil Administered Once Daily for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Dose Finding Study. J Urol. 2008;180:1228–34. Randomized placebo-controlled study investigating the effect of Tadalafil on LUTS, which also examines differences in dosing.PubMedCrossRefGoogle Scholar
  40. 40.
    • Porst H, McVary KT, Montorsi F, Sutherland P, Elion-Mboussa A, Wolka AM, et al. Effects of Once-Daily Tadalafil on Erectile Function in Men with Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia. Eur Urol. 2009;56. Randomized placebo-controlled study investigating the effect of Tadalafil on LUTS.Google Scholar
  41. 41.
    • Nihad AM, Tamimi, Ivan Mincik, Scott Haughie, Janice Lamb, Anna Crossland and Peter Ellis A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia. BJU Int 2010. Randomized placebo-controlled study investigating the effect of UK-369,003 on LUTS.Google Scholar
  42. 42.
    • Hartmut Porst, Edward D. Kim, Adolfo R. Casabé, Vincenzo Mirone, Roberta J. Secrest, Lei Xu, David P. Sundin, Lars Viktrup, for the LVHJ study team Efficacy and Safety of Tadalafil Once Daily in the Treatment of Men With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Results of an International Randomized, Double-Blind, Placebo-Controlled Trial. Eur Urol 2011. Randomized placebo-controlled study investigating the effect of Tadalafil on LUTS. Google Scholar
  43. 43.
    Dmochowski R, Roehrborn C, Klise S, Xu L, Kaminetsky J, Kraus S. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. J Urol. 2010;183(3):1092–7.PubMedCrossRefGoogle Scholar
  44. 44.
    •• Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012;61(5):994–1003. Comprehensive meta-analysis of the use of PDE5Is for LUTS, including randomized placebo-controlled trials as well as trials comparing combination therapy with alpha-blockers.PubMedCrossRefGoogle Scholar
  45. 45.
    Donatucci CF, Brock GB, Goldfischer ER, Pommerville PJ, Elion-Mboussa A, Kissel JD, et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. BJU Int. 2011;107:1110-6-S11.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Division of UrologySouthern Illinois University School of MedicineSpringfieldUSA

Personalised recommendations